Reports Q2 revenue $59.95M, consensus $67.14M. Frederick Vogt, Interim President and Chief Executive Officer of Iovance, stated, “In the first half of 2025, we continued to drive U.S. adoption for Amtagvi in advanced melanoma, surpassing more than 100 patients treated within a single quarter. Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients. We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics options imply 23.8% move in share price post-earnings
- Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer
- Unusually active option classes on open July 23rd
- Iovance Biotherapeutics Gains Competitive Edge as Replimune Faces FDA Setback
- Realty Income, GitLab, DoorDash, Iovance, Senseonics: Trending by Analysts